噬菌体治疗泛耐药鲍氏不动杆菌重症感染小鼠的研究
|
摘要
目的探讨噬菌体治疗泛耐药鲍氏不动杆菌重症感染小鼠的疗效。方法以SPF级昆明小鼠建立小鼠感染泛耐药鲍氏不动杆菌的模型,分为实验组和对照组,实验组使用噬菌体AB46治疗,对照组给同等体积的肉汤治疗,统计比较两组小鼠的生存率,进行脾菌数分析。结果泛耐药鲍氏不动杆菌1∶10稀释实验组与对照组P=0.020<0.05,有统计学差异;1∶2、1∶5稀释组分别为P=0.650,P=0.170,均>0.05,无统计学差异;1∶50稀释的实验组与对照组均无小鼠死亡,脾菌数计数结果 P=0.026,有统计学差异。结论噬菌体治疗泛耐药鲍氏不动杆菌重症感染小鼠是一种有效的治疗方法,可明显提高小鼠的生存率,在感染较轻的情况下可以明显降低小鼠的脾菌数。
We explored the effect of therapy with bacteriophages for pandrug resistant Acinetobacter baumannii infections.Kunming mice(Specific Pathogen Free)were divided into two groups:experimental group(severe infection caused by pandrug resistant Acinetobacter baumannii)and the control group.The mice of experimental group were treated with Phages AB46 while the mice of control group were treated with broth.The survival rate was compared with statistical method and the spleen bacteria count was analyzed.Results showed that there were statistical difference between the experimental group and control group of Pandrug resistant Acinetobacter baumannii groups of 1∶10 dilution,P=0.020<0.05.There were no statistical difference between each two groups of 1∶2(P=0.650)and 1∶5(P=0.170)dilution,both were>0.05.There were no dead mice in groups of 1∶50 dilution with statistical difference of spleen bacteria count,P=0.026.Therapy with phages was an effective method to control infection caused by Pandrug resistant Acinetobacter baumannii which could increase the survival rate and decrease spleen bacteria count of the mice with light infection.
We explored the effect of therapy with bacteriophages for pandrug resistant Acinetobacter baumannii infections.Kunming mice(Specific Pathogen Free)were divided into two groups:experimental group(severe infection caused by pandrug resistant Acinetobacter baumannii)and the control group.The mice of experimental group were treated with Phages AB46 while the mice of control group were treated with broth.The survival rate was compared with statistical method and the spleen bacteria count was analyzed.Results showed that there were statistical difference between the experimental group and control group of Pandrug resistant Acinetobacter baumannii groups of 1∶10 dilution,P=0.020<0.05.There were no statistical difference between each two groups of 1∶2(P=0.650)and 1∶5(P=0.170)dilution,both were>0.05.There were no dead mice in groups of 1∶50 dilution with statistical difference of spleen bacteria count,P=0.026.Therapy with phages was an effective method to control infection caused by Pandrug resistant Acinetobacter baumannii which could increase the survival rate and decrease spleen bacteria count of the mice with light infection.
引文
[1]Peleg AY,Seifert H,Paterson DL,Aeinetobaeter baumannii;emergenec of a successful pathogen[J].Clin Microbiol Rev,2008,21(3):538-582.
[2]Dijkshoorn L,Nemec A,Selferr H.An increasing threat in hospitals:multidrug-resistant Aeinetobaeter baumannii[J].Nat Rev-Microbiol,2007,5(12):939-951.
[3]Gong Y,Chen J,Liu C,et al.Comparison of pathogens anti antibiotic resistance of burn patients in the burn ICU or in the common burn ward[J].Burns,2014,40(3):402-407.
[4]Hu FP,Zhu DM,Wang F,et al.Surveillance of bacterial resistance in CHINET China 2014[J].J Chin Infect Chemother,2015,15(15):401-410.(in Chinese)胡付品,朱德妹,汪复等.2014年CHINET中国细菌耐药性监测[J].中国感染与化疗杂志,2015,15(15):401-410.
[5]Karaiskos I,Giamarellou H.Muhidrug-resistant and extensively drug-resistant Gram-negative pathogens:current and emerging therapeutic approaches[J].Expert Opin Pharmacother,2014,15(10):1351-1370.
[6]Visea P,Seifert H,Towner KJ.Aeinetobaeter inketion-an emerging threat to human health[J].IUBMB Life,2011,63(12):1048-1054.
[7]Hauser AR,Meesas J,Moir DT.Beyond antibiotics new therapeutic approaches for bacterial infections[J].Clin Infect Dis,2016,63(1):89-95.
[8]Kutter EM,Kuhl SJ,Ahedon ST.Re-establishing aplace for phage therapy in western medicine[J].Future Mierobiol,2015,10(5):685-688.
[9]Long Z,Zhou YF.Research status of antibacterial treatment of non antibiotic substances[J].Clinical Pediatr,2015,33(6):592-596.(in Chinese)龙智,周云芳.非抗生素物质抗菌治疗的研究现状[J].临床儿科杂志,2015,33(6):592-596.
[10]Karlowsky A,Draghi DC,Jones ME,et al.Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginos and Acinetobacter baumannii from hospitalized patients in the United States,1998to 2001[J].Antimicrob A gents Chemother,2003,47:1681-1688.
[11]Hu B,Jing W,Yan Q,et al.Study of bacteriophage treatment of imipenem resistant Pseudomonas aeruginosa in mice[J].Chin J Micro and Immun,2006,26(5):438-441.(in Chinese)胡北,王晶,严群,等.噬菌体治疗实验性小鼠耐亚胺培南铜绿假单胞菌感染的研究[J].中华微生物学和免疫学杂志,2006,26(5):438-441.
[12]Aslanov BI,Iafaev RK,Zueva LP.Mode of the rational use of Pseudomonas aeruginosa bacteriophages in therapeutic and epidemic control practice[J].Zh Mikrobiol Epidemiol Immunobiol,2003,(5):72-76.
[13]Smiths HW,Huggine MB.Successful treatment of phage Escherichia coli infections in mice using phages:its general superiority over antibiotics[J].Gen Microbiol,1982,128(2):307-318.
[14]Alexander S,Zemphira A,Glenn J.Bacteriophage therapy[J].Antimicrob Agents Chemother,2001,45(3):649.
[2]Dijkshoorn L,Nemec A,Selferr H.An increasing threat in hospitals:multidrug-resistant Aeinetobaeter baumannii[J].Nat Rev-Microbiol,2007,5(12):939-951.
[3]Gong Y,Chen J,Liu C,et al.Comparison of pathogens anti antibiotic resistance of burn patients in the burn ICU or in the common burn ward[J].Burns,2014,40(3):402-407.
[4]Hu FP,Zhu DM,Wang F,et al.Surveillance of bacterial resistance in CHINET China 2014[J].J Chin Infect Chemother,2015,15(15):401-410.(in Chinese)胡付品,朱德妹,汪复等.2014年CHINET中国细菌耐药性监测[J].中国感染与化疗杂志,2015,15(15):401-410.
[5]Karaiskos I,Giamarellou H.Muhidrug-resistant and extensively drug-resistant Gram-negative pathogens:current and emerging therapeutic approaches[J].Expert Opin Pharmacother,2014,15(10):1351-1370.
[6]Visea P,Seifert H,Towner KJ.Aeinetobaeter inketion-an emerging threat to human health[J].IUBMB Life,2011,63(12):1048-1054.
[7]Hauser AR,Meesas J,Moir DT.Beyond antibiotics new therapeutic approaches for bacterial infections[J].Clin Infect Dis,2016,63(1):89-95.
[8]Kutter EM,Kuhl SJ,Ahedon ST.Re-establishing aplace for phage therapy in western medicine[J].Future Mierobiol,2015,10(5):685-688.
[9]Long Z,Zhou YF.Research status of antibacterial treatment of non antibiotic substances[J].Clinical Pediatr,2015,33(6):592-596.(in Chinese)龙智,周云芳.非抗生素物质抗菌治疗的研究现状[J].临床儿科杂志,2015,33(6):592-596.
[10]Karlowsky A,Draghi DC,Jones ME,et al.Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginos and Acinetobacter baumannii from hospitalized patients in the United States,1998to 2001[J].Antimicrob A gents Chemother,2003,47:1681-1688.
[11]Hu B,Jing W,Yan Q,et al.Study of bacteriophage treatment of imipenem resistant Pseudomonas aeruginosa in mice[J].Chin J Micro and Immun,2006,26(5):438-441.(in Chinese)胡北,王晶,严群,等.噬菌体治疗实验性小鼠耐亚胺培南铜绿假单胞菌感染的研究[J].中华微生物学和免疫学杂志,2006,26(5):438-441.
[12]Aslanov BI,Iafaev RK,Zueva LP.Mode of the rational use of Pseudomonas aeruginosa bacteriophages in therapeutic and epidemic control practice[J].Zh Mikrobiol Epidemiol Immunobiol,2003,(5):72-76.
[13]Smiths HW,Huggine MB.Successful treatment of phage Escherichia coli infections in mice using phages:its general superiority over antibiotics[J].Gen Microbiol,1982,128(2):307-318.
[14]Alexander S,Zemphira A,Glenn J.Bacteriophage therapy[J].Antimicrob Agents Chemother,2001,45(3):649.